161 related articles for article (PubMed ID: 33247498)
21. Experimental in vitro, ex vivo and in vivo models in prostate cancer research.
Sailer V; von Amsberg G; Duensing S; Kirfel J; Lieb V; Metzger E; Offermann A; Pantel K; Schuele R; Taubert H; Wach S; Perner S; Werner S; Aigner A
Nat Rev Urol; 2023 Mar; 20(3):158-178. PubMed ID: 36451039
[TBL] [Abstract][Full Text] [Related]
22. A multi-organ-chip co-culture of liver and testis equivalents: a first step toward a systemic male reprotoxicity model.
Baert Y; Ruetschle I; Cools W; Oehme A; Lorenz A; Marx U; Goossens E; Maschmeyer I
Hum Reprod; 2020 May; 35(5):1029-1044. PubMed ID: 32390056
[TBL] [Abstract][Full Text] [Related]
23. Applications of patient-derived tumor xenograft models and tumor organoids.
Yoshida GJ
J Hematol Oncol; 2020 Jan; 13(1):4. PubMed ID: 31910904
[TBL] [Abstract][Full Text] [Related]
24. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
25. Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses.
Pappas KJ; Choi D; Sawyers CL; Karthaus WR
J Vis Exp; 2019 Oct; (152):. PubMed ID: 31710046
[TBL] [Abstract][Full Text] [Related]
26. Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
Joshi A; Roberts MJ; Alinezhad S; Williams ED; Vela I
BJU Int; 2020 Jul; 126(1):65-72. PubMed ID: 32383524
[TBL] [Abstract][Full Text] [Related]
27. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
28. Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer.
Ellis L; Ku S; Li Q; Azabdaftari G; Seliski J; Olson B; Netherby CS; Tang DG; Abrams SI; Goodrich DW; Pili R
Prostate; 2016 Sep; 76(13):1192-202. PubMed ID: 27225803
[TBL] [Abstract][Full Text] [Related]
29. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice.
Bartucci M; Ferrari AC; Kim IY; Ploss A; Yarmush M; Sabaawy HE
Front Cell Dev Biol; 2016; 4():64. PubMed ID: 27446916
[TBL] [Abstract][Full Text] [Related]
30. Organoid technology and applications in cancer research.
Xu H; Lyu X; Yi M; Zhao W; Song Y; Wu K
J Hematol Oncol; 2018 Sep; 11(1):116. PubMed ID: 30219074
[TBL] [Abstract][Full Text] [Related]
31. Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers.
Seo E; Kang M
BMB Rep; 2023 Jan; 56(1):24-31. PubMed ID: 36476272
[TBL] [Abstract][Full Text] [Related]
32. Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.
Valta MP; Zhao H; Saar M; Tuomela J; Nolley R; Linxweiler J; Sandholm J; Lehtimäki J; Härkönen P; Coleman I; Nelson PS; Corey E; Peehl DM
Clin Exp Metastasis; 2016 Apr; 33(4):325-37. PubMed ID: 26873136
[TBL] [Abstract][Full Text] [Related]
33. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
34. Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells.
Usui T; Sakurai M; Nishikawa S; Umata K; Nemoto Y; Haraguchi T; Itamoto K; Mizuno T; Noguchi S; Mori T; Iwai S; Nakagawa T; Yamawaki H; Ohama T; Sato K
Cancer Sci; 2017 Dec; 108(12):2383-2392. PubMed ID: 29024204
[TBL] [Abstract][Full Text] [Related]
35. Organoid models in gynaecological oncology research.
Semertzidou A; Brosens JJ; McNeish I; Kyrgiou M
Cancer Treat Rev; 2020 Nov; 90():102103. PubMed ID: 32932156
[TBL] [Abstract][Full Text] [Related]
36. Culture of Bladder Cancer Organoids as Precision Medicine Tools.
Thomas PB; Perera MPJ; Alinezhad S; Joshi A; Saadat P; Nicholls C; Devonport CP; Calabrese AR; Templeton AR; Wood JR; Mackenzie NJ; Jeffery PL; Vela I; Williams ED
J Vis Exp; 2021 Dec; (178):. PubMed ID: 35037658
[TBL] [Abstract][Full Text] [Related]
37. Organoids: An intermediate modeling platform in precision oncology.
Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
[TBL] [Abstract][Full Text] [Related]
38. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
39. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
[TBL] [Abstract][Full Text] [Related]
40. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
